what about the low volume buying and selling forces we are seeing these days, shouldt the proprietary deterrent abuse property be generating much interest in this biotech field now that the focus is currently on creating opoid abuse resistant products demanded for quick approval and perhaps an accelerated approval process to get it on the market? I think the volume should go up increasingly day after day, signifying the importance of such drugs in the market that is underserved, has a huge potential market to capture and will be beneficial to many patients.
News 
Market Data 
Discover 
